To systematically review the effects of Qili Qiangxin capsule treating chronic heart failure.Methods：Clinical trials on Qili Qiangxin capsules treating chronic heart failure(CHF) published during 2008 and September 2013 were searched from the following electronic databases including Cochrane Library, Embase, PubMed, CNKI, CBM, Wanfang, VIP. Altogether 28 studies including 2536 patients were included in the review, and the data were analyzed by using Review Manager 5.0.Results：Qili Qiangxin capsule can improve the prognosis of chronic heart failure. Meta-analysis results showed that, 1) Reducing the levels of N-terminal Pro of Pro-brain natriuretic peptide (NT-pro BNP) and brain natriuretic peptide(BNP)：the level of NT-pro BNP of the treatment group was lower than that of the control group ［SMD=-1.57,95%CI(-1.79,-1.34),P<0. 000 01］,the level of BNP in treatment was lower than that of the control group ［SMD=-0.60,95%CI(-0.77,-0.43),P<0.000 01］; 2) Treatment group better improved cardiac function NYHA ［OR=3.48．95% CI(2.66，4.55)，P<0.000 01］;3) The distance of 6-minute walking test was longer in treatment group ［SMD=1.03,95%CI(0.91,1.16),P<0.000 01］;4) Treatment group better improved the left ventricular ejection fraction ［SMD=1.06,95%CI(0.96,1.16),P<0.000 01］; 5) The incidence of adverse reactions was lower in treatment group ［OR=0.23．95% CI(0.11，0.47)，P<0.000 01］.Conclusion：Qili Qiangxin Capsule can obviously improve the cardiac function and the quality of life of patients with chronic heart failure, and it is safe and effective.